文献速递支持与姑息治疗

癌症免疫治疗毒性综述

A review of cancer immunotherapy toxicity.
PubMed 文献 · CA Cancer J Clin · 2020-01-16

该综述聚焦免疫检查点抑制剂与嵌合抗原受体T细胞疗法的毒性,阐述其病理生理、诊断与管理。免疫治疗可诱导多种实体瘤与血液肿瘤的持久缓解,但毒性谱独特,常需类固醇及免疫调节治疗,并已有共识指南。

要点

  • 免疫检查点抑制剂与CAR-T细胞毒性谱独特,取决于作用机制。
  • 毒性管理常需类固醇和免疫调节治疗,已有共识指南。
  • 综述涵盖病理生理、诊断与管理三方面。

核心结论

  • 癌症免疫治疗可诱导多种实体瘤和血液肿瘤的持久缓解,但毒性谱独特且常需特定管理。

研究设计与样本

  • 综述,聚焦检查点抑制剂和嵌合抗原受体T细胞的毒性,涵盖病理生理、诊断和管理。

主要发现

  • 免疫治疗毒性取决于作用机制,与其他癌症治疗毒性不同。
  • 毒性管理常包括类固醇和免疫调节治疗。

临床怎么用

  • 肿瘤内科医生需识别免疫治疗独特毒性,并按共识指南使用类固醇和免疫调节治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cancer immunotherapies, including checkpoint inhibitors and adoptive cell therapy, manipulate the immune system to recognize and attack cancer cells. These therapies have the potential to induce durable responses in multiple solid and hematologic malignancies and thus have transformed treatment algorithms for numerous tumor types. Cancer immunotherapies lead to unique toxicity profiles distinct from the toxicities of other cancer therapies, depending on their mechanism of action. These toxicities often require specific management, which can include steroids and immune-modulating therapy and for which consensus guidelines have been published. This review will focus on the toxicities of checkpoint inhibitors and chimeric antigen receptor T cells, including pathophysiology, diagnosis, and management.

来源:CA Cancer J Clin,查看原文。版权归原作者所有。

引用

  1. Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020. PMID: 31944278. doi:10.3322/caac.21596

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。